Literature DB >> 15863151

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.

Tao Zhang1, Ming Guan, Hong Yan Jin, Yuan Lu.   

Abstract

OBJECTIVE: Cisplatin (DDP) resistance is a major barrier to overcome before chemotherapy can become curative for most patients presenting with ovarian cancer. In this study, we investigated the effect of siRNAs on expression of p-gp, GST-pi mRNA and protein in cisplatin-resistant human ovarian cancer cells in order to restore sensitivity to DDP.
METHODS: Small interfering double-stranded RNAs (siRNA) were designed to target p-glycoprotein (p-gp) and glutathione S-transferases (GST) mRNA as a strategy to inhibit both resistant gene expression at the mRNA level. Using Real-Time PCR and western blotting assay the changes of the RNA and protein levels of both drug resistant genes were studied.
RESULTS: Transfection of MDR-1 and GST siRNAs into human multi-drug resistance (MDR) ovarian cancer cell lines, COC1/DDP and SKOV3/DDP, resulted in a time-dependent inhibition of both gene expressions with the decline of the IC(50) values but had no effect on the expression of a-Tubulin. Inhibition of P-gp and GST expression by siRNA enhanced the intracellular accumulation of and restored sensitivity to DDP.
CONCLUSIONS: These studies suggest that p-gp and GST siRNAs are effective inhibitors of MDR gene expression and reverse the resistance of ovarian carcinomas. Our studies may provide a new insight to develop siRNAs as a novel therapeutic tool for the treatment of ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863151     DOI: 10.1016/j.ygyno.2005.01.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.

Authors:  Meysam Abbasi; Hamidreza Montazeri Aliabadi; Elaine H Moase; Afsaneh Lavasanifar; Kamaljit Kaur; Raymond Lai; Charles Doillon; Hasan Uludağ
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

2.  Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells.

Authors:  Hanxue Zou; Hongxia Li
Journal:  Exp Ther Med       Date:  2019-09-30       Impact factor: 2.447

3.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

4.  MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.

Authors:  Shuo Chen; Jin-Wen Jiao; Kai-Xuan Sun; Zhi-Hong Zong; Yang Zhao
Journal:  Drug Des Devel Ther       Date:  2015-09-16       Impact factor: 4.162

5.  MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.

Authors:  Kai-Xuan Sun; Jin-Wen Jiao; Shuo Chen; Bo-Liang Liu; Yang Zhao
Journal:  J Ovarian Res       Date:  2015-12-02       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.